Tissue factor in tumor microenvironment: A systematic review

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Han, Xiao ^a   Guo, Bo ^a   Li, Yongsheng ^a,b   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Coagulation; Microparticles; Tissue factor; Tumor microenvironment; Venous thromboembolism

Indexed keywords

DNA TOPOISOMERASE; GAMMA INTERFERON; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 1; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; THROMBOPLASTIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DEEP VEIN THROMBOSIS; FIBRIN DEPOSITION; HUMAN; LUNG CANCER; LUNG EMBOLISM; MELANOMA; METASTASIS; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BLOOD CLOTTING; COMPLICATION; HEMOSTASIS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; HEMOSTASIS; HUMANS; NEOPLASMS; THROMBOPLASTIN; TUMOR MICROENVIRONMENT; VENOUS THROMBOEMBOLISM;

EID: 84906929466     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0054-8     Document Type: Review

References (93)

1. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. EK Spicer, R Horton, L Bloem, R Bach, KR Williams, A Guha, J Kraus, TC Lin, Y Nemerson, WH Konigsberg, Proc Natl Acad Sci U S A 1987 84 5148 5152 10.1073/pnas.84.15.5148 3037536
2. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling? HH Versteeg, MP Peppelenbosch, CA Spek, Thromb Haemost 2001 86 1353 1359 11776298
3. SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells. JG Tardos, A Eisenreich, G Deikus, DH Bechhofer, S Chandradas, U Zafar, U Rauch, VY Bogdanov, J Thromb Haemost 2008 6 877 884 10.1111/j.1538-7836.2008.02946.x 18315555
4. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. VY Bogdanov, V Balasubramanian, J Hathcock, O Vele, M Lieb, Y Nemerson, Nat Med 2003 9 458 462 10.1038/nm841 12652293
5. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. B Szotowski, S Antoniak, W Poller, HP Schultheiss, U Rauch, Circ Res 2005 96 1233 1239 10.1161/01.RES.0000171805.24799.fa 15920023
6. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. A Eisenreich, VY Bogdanov, A Zakrzewicz, A Pries, S Antoniak, W Poller, HP Schultheiss, U Rauch, Circ Res 2009 104 589 599 10.1161/CIRCRESAHA.108.183905 19168442
7. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. P Censarek, A Bobbe, M Grandoch, K Schror, AA Weber, Thromb Haemost 2007 97 11 14 17200764
8. Alternatively spliced tissue factor: discovery, insights, clinical implications. R Srinivasan, VY Bogdanov, Front Biosci 2011 16 3061 3071 10.2741/3899
9. Cancer-associated thrombosis. RL Bick, N Engl J Med 2003 349 109 111 10.1056/NEJMp030086 12853582
10. Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell. YJ Yu, YM Li, XD Hou, C Guo, N Cao, ZY Jiao, Asian Pac J Cancer Prev 2012 13 1845 1849 10.7314/APJCP.2012.13.5.1845 22901134
11. Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. A Eisenreich, U Boltzen, R Malz, HP Schultheiss, U Rauch, Circ J 2011 75 1235 1242 10.1253/circj.CJ-10-0783 21389637
12. Alternatively spliced tissue factor promotes breast cancer growth in a beta1 integrin-dependent manner. B Kocaturk, YW Van den Berg, C Tieken, JS Mieog, EM de Kruijf, CC Engels, MA van der Ent, PJ Kuppen, CJ Van de Velde, W Ruf, PH Reitsma, S Osanto, GJ Liefers, VY Bogdanov, HH Versteeg, Proc Natl Acad Sci U S A 2013 110 11517 11522 10.1073/pnas.1307100110 23801760
13. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Y Liu, P Jiang, K Capkova, D Xue, L Ye, SC Sinha, N Mackman, KD Janda, C Liu, Cancer Res 2011 71 6492 6502 10.1158/0008-5472.CAN-11-1145 21880589
14. The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody. Y Saito, Y Hashimoto, J Kuroda, M Yasunaga, Y Koga, A Takahashi, Y Matsumura, Eur J Cancer 2011 47 2230 2239 10.1016/j.ejca.2011.04.028 21621407
15. Tissue factor proangiogenic signaling in cancer progression. F Schaffner, N Yokota, W Ruf, Thromb Res 2012 129 Suppl 1 127 S131 10.1016/S0049-3848(12)70032-4 22682123
16. Tissue factor expression determines tumour cell coagulation kinetics. J Welsh, JD Smith, KR Yates, J Greenman, A Maraveyas, LA Madden, Int J Lab Hematol 2012 34 396 402 10.1111/j.1751-553X.2012.01409.x 22348286
17. Immuno-PET of tissue factor in pancreatic cancer. H Hong, Y Zhang, TR Nayak, JW Engle, HC Wong, B Liu, TE Barnhart, W Cai, J Nucl Med 2012 53 1748 1754 10.2967/jnumed.112.105460 22988057
18. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. E Cocco, J Varughese, N Buza, S Bellone, M Glasgow, M Bellone, P Todeschini, L Carrara, DA Silasi, M Azodi, PE Schwartz, TJ Rutherford, S Pecorelli, CJ Lockwood, AD Santin, BMC Cancer 2011 11 263 10.1186/1471-2407-11-263 21693061
19. Microparticles in hemostasis and thrombosis. AP Owens 3rd, N Mackman, Circ Res 2011 108 1284 1297 10.1161/CIRCRESAHA.110.233056 21566224
20. Microparticles in cancer. J Rak, Semin Thromb Hemost 2010 36 888 906 10.1055/s-0030-1267043 21049390
21. Membrane microvesicles: macromessengers in cancer disease and progression. D Castellana, F Toti, JM Freyssinet, Thromb Res 2010 125 Suppl 2 84 S88 10.1016/S0049-3848(10)70021-9 20434014
22. Biomarkers for prediction of venous thromboembolism in cancer. I Pabinger, J Thaler, C Ay, Blood 2013 122 2011 2018 10.1182/blood-2013-04-460147 23908470
23. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. A Bharthuar, AA Khorana, A Hutson, JG Wang, NS Key, N Mackman, RV Iyer, Thromb Res 2013 132 180 184 10.1016/j.thromres.2013.06.026 23856554
24. Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism. Z Ma, T Zhang, R Wang, Z Cheng, H Xu, W Li, Y Wang, X Wang, Int J Gynecol Cancer 2011 21 616 624 10.1097/IGC.0b013e3182150e98 21543928
25. Tissue factor as a novel target for treatment of breast cancer. M Cole, M Bromberg, Oncologist 2013 18 14 18 10.1634/theoncologist.2012-0322 23287882
26. Thromboembolic disease in patients with high-grade glioma. JR Perry, Neuro Oncol 2012 14 Suppl 4 v73 iv80 10.1093/neuonc/nos197 23095833
27. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. J Thaler, C Ay, N Mackman, S Metz-Schimmerl, J Stift, A Kaider, L Mullauer, M Gnant, W Scheithauer, I Pabinger, Eur J Clin Invest 2013 43 277 285 10.1111/eci.12042 23398637
28. Tissue factor expression is a clinical indicator of lymphatic metastasis and poor prognosis in gastric cancer with intestinal phenotype. H Yamashita, J Kitayama, M Ishikawa, H Nagawa, J Surg Oncol 2007 95 324 331 10.1002/jso.20680 17066404
29. Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines. BA Lwaleed, L Lam, M Lasebai, AJ Cooper, Blood Coagul Fibrinolysis 2013 24 339 343 10.1097/MBC.0b013e32835e98a6 23524311
30. Hyperthermia synergizes with tissue factor knockdown to suppress the growth and hepatic metastasis of colorectal cancer in orthotopic tumor model. H Li, ML Tian, G Yu, YC Liu, X Wang, J Zhang, SQ Ji, J Zhu, YL Wan, JQ Tang, J Surg Oncol 2012 106 689 695 10.1002/jso.23136 22532129
31. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. A Eisenreich, A Zakrzewicz, K Huber, H Thierbach, W Pepke, P Goldin-Lang, HP Schultheiss, A Pries, U Rauch, Oncol Rep 2013 30 462 470 23604472
32. Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-kappaB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. Y Zhao, D Zhang, S Wang, L Tao, A Wang, W Chen, Z Zhu, S Zheng, X Gao, Y Lu, PLoS One 2013 8 56557 10.1371/journal.pone.0056557 23437168
33. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. JL Yu, JW Rak, J Thromb Haemost 2004 2 2065 2067 10.1111/j.1538-7836.2004.00972.x 15550054
34. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. J Contrino, G Hair, DL Kreutzer, FR Rickles, Nat Med 1996 2 209 215 10.1038/nm0296-209 8574967
35. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. JA Vrana, MT Stang, JP Grande, MJ Getz, Cancer Res 1996 56 5063 5070 8895765
36. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. YW van den Berg, LG van den Hengel, HR Myers, O Ayachi, E Jordanova, W Ruf, CA Spek, PH Reitsma, VY Bogdanov, HH Versteeg, Proc Natl Acad Sci U S A 2009 106 19497 19502 10.1073/pnas.0905325106 19875693
37. Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models. RC Godby, YW Van Den Berg, R Srinivasan, R Sturm, DY Hui, SF Konieczny, BJ Aronow, E Ozhegov, W Ruf, HH Versteeg, VY Bogdanov, Mol Med 2012 18 771 779 10.2119/molmed.2011.00416 22481268
38. Regulation of tissue factor coagulant activity on cell surfaces. LV Rao, UR Pendurthi, J Thromb Haemost 2012 10 2242 2253 10.1111/jth.12003 23006890
39. Microvesicles as risk markers for venous thrombosis. PE Rautou, N Mackman, Expert Rev Hematol 2013 6 91 101 10.1586/ehm.12.74 23373784
40. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. B Rao, Y Gao, J Huang, X Gao, X Fu, M Huang, J Yao, J Wang, W Li, J Zhang, H Liu, L Wang, Int J Colorectal Dis 2011 26 593 601 10.1007/s00384-011-1164-1 21404058
41. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. JL Yu, L May, V Lhotak, S Shahrzad, S Shirasawa, JI Weitz, BL Coomber, N Mackman, JW Rak, Blood 2005 105 1734 1741 10.1182/blood-2004-05-2042 15494427
42. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. N Magnus, D Garnier, J Rak, Blood 2010 116 815 818 10.1182/blood-2009-10-250639 20462964
43. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Y Rong, VE Belozerov, C Tucker-Burden, G Chen, DL Durden, JJ Olson, EG Van Meir, N Mackman, DJ Brat, Cancer Res 2009 69 2540 2549 10.1158/0008-5472.CAN-08-1547 19276385
44. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. A Eisenreich, R Malz, W Pepke, Y Ayral, W Poller, HP Schultheiss, U Rauch, Circ J 2009 73 1746 1752 10.1253/circj.CJ-99-0225 19597299
45. c-Met activation in medulloblastoma induces tissue factor expression and activity: effects on cell migration. M Provencal, D Labbe, R Veitch, D Boivin, GE Rivard, H Sartelet, Y Robitaille, D Gingras, R Beliveau, Carcinogenesis 2009 30 1089 1096 10.1093/carcin/bgp085 19359592
46. Tumor necrosis factor alpha interferes with the cell cycle of normal and papillomavirus-immortalized human keratinocytes. KB Vieira, DJ Goldstein, LL Villa, Cancer Res 1996 56 2452 2457 8625327
47. Cancer genes and the pathways they control. B Vogelstein, KW Kinzler, Nat Med 2004 10 789 799 10.1038/nm1087 15286780
48. Tissue factor is involved in retinoblastoma cell proliferation via both the Akt and extracellular signal-regulated kinase pathways. BJ Lee, JH Kim, SH Woo, JH Kim, DH Kim, YS Yu, Oncol Rep 2011 26 665 670 21617868
49. Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. L Sun, Y Liu, S Lin, J Shang, J Liu, J Li, S Yuan, L Zhang, Acta Oncol 2013 52 842 851 10.3109/0284186X.2013.705890 23409769
50. Interferon-gamma and tumor necrosis factor-alpha act synergistically to up-regulate tissue factor in alveolar epithelial cells. JA Bastarache, SC Sebag, BS Grove, LB Ware, Exp Lung Res 2011 37 509 517 10.3109/01902148.2011.605512 21913843
51. TGF-beta1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. M Wygrecka, D Zakrzewicz, B Taborski, M Didiasova, G Kwapiszewska, KT Preissner, P Markart, Am J Respir Cell Mol Biol 2012 47 614 627 10.1165/rcmb.2012-0097OC 22771387
52. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. O Fedorov, K Huber, A Eisenreich, P Filippakopoulos, O King, AN Bullock, D Szklarczyk, LJ Jensen, D Fabbro, J Trappe, U Rauch, F Bracher, S Knapp, Chem Biol 2011 18 67 76 10.1016/j.chembiol.2010.11.009 21276940
53. Regulation of vascular function on posttranscriptional level. A Eisenreich, Thrombosis 2013 2013 948765 10.1155/2013/948765 24288605
54. The impact of microRNAs on the regulation of tissue factor biology. A Eisenreich, U Leppert, Trends Cardiovasc Med 2014 24 128 132 10.1016/j.tcm.2013.09.005 24120358
55. Regulation of the tissue factor isoform expression and thrombogenicity of HMEC-1 by miR-126 and miR-19a. E A, U Rauch, Cell Biol: Res Ther 2013 2 1 doi:10.4172/2324-9293.1000101
56. MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. G Yu, H Li, X Wang, T Wu, J Zhu, S Huang, Y Wan, J Tang, Mol Cell Biochem 2013 380 239 247 10.1007/s11010-013-1679-6 23666757
57. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. R Teruel, C Perez-Sanchez, J Corral, MT Herranz, V Perez-Andreu, E Saiz, N Garcia-Barbera, I Martinez-Martinez, V Roldan, V Vicente, C Lopez-Pedrera, C Martinez, J Thromb Haemost 2011 9 1985 1992 10.1111/j.1538-7836.2011.04451.x 21794077
58. Genetic pathways linking hemostasis and cancer. D Garnier, N Magnus, E D'Asti, M Hashemi, B Meehan, C Milsom, J Rak, Thromb Res 2012 129 Suppl 1 22 S29 10.1016/S0049-3848(12)70012-9 22682129
59. Leppert U, Eisenreich A: The role of tissue factor isoforms in cancer biology. Int J Cancer 2014, doi:10.1002/ijc.28959.
60. The relationship between tissue factor and cancer progression: insights from bench and bedside. YW van den Berg, S Osanto, PH Reitsma, HH Versteeg, Blood 2012 119 924 932 10.1182/blood-2011-06-317685 22065595
61. Involvement of PKCalpha activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. B Wu, H Zhou, L Hu, Y Mu, Y Wu, Tumour Biol 2013 34 837 846 10.1007/s13277-012-0614-x 23233043
62. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. L Hu, L Xia, H Zhou, B Wu, Y Mu, Y Wu, J Yan, Tumour Biol 2013 34 2573 2581 10.1007/s13277-013-0803-2 23616010
63. Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). M Aberg, M Johnell, M Wickstrom, A Siegbahn, Thromb Res 2011 127 141 148 10.1016/j.thromres.2010.11.015 21168190
64. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. M Signaevsky, J Hobbs, J Doll, N Liu, GA Soff, Semin Thromb Hemost 2008 34 161 169 10.1055/s-2008-1079256 18645921
65. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. JE Hobbs, A Zakarija, DL Cundiff, JA Doll, E Hymen, M Cornwell, SE Crawford, N Liu, M Signaevsky, GA Soff, Thromb Res 2007 120 Suppl 2 13 S21 10.1016/S0049-3848(07)70126-3 18023707
66. Protease-activated receptor-2 induces proinflammatory cytokine and chemokine gene expression in canine keratinocytes. S Maeda, S Maeda, K Ohno, N Kaji, M Hori, Y Fujino, H Tsujimoto, Vet Immunol Immunopathol 2013 153 17 25 10.1016/j.vetimm.2013.01.018 23465358
67. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. A Dorfleutner, E Hintermann, T Tarui, Y Takada, W Ruf, Mol Biol Cell 2004 15 4416 4425 10.1091/mbc.E03-09-0640 15254262
68. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. I Ott, B Weigand, R Michl, I Seitz, N Sabbari-Erfani, FJ Neumann, A Schomig, Circulation 2005 111 349 355 10.1161/01.CIR.0000153333.52294.42 15642762
69. Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells. M Muller, S Albrecht, F Golfert, A Hofer, RH Funk, V Magdolen, C Flossel, T Luther, Exp Cell Res 1999 248 136 147 10.1006/excr.1999.4395 10094821
70. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. JS Palumbo, Semin Thromb Hemost 2008 34 154 160 10.1055/s-2008-1079255 18645920
71. Thrombin generation and the pathogenesis of cancer. W Ruf, BM Mueller, Semin Thromb Hemost 2006 32 Suppl 1 61 68 10.1055/s-2006-939555 16673267
72. Hemostatic factors, innate immunity and malignancy. JL Degen, JS Palumbo, Thromb Res 2012 129 Suppl 1 1 S5 10.1016/S0049-3848(12)70143-3 22682116
73. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. JS Palumbo, KA Barney, EA Blevins, MA Shaw, A Mishra, MJ Flick, KW Kombrinck, KE Talmage, M Souri, A Ichinose, JL Degen, J Thromb Haemost 2008 6 812 819 10.1111/j.1538-7836.2008.02938.x 18315549
74. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. A Amirkhosravi, T Meyer, JY Chang, M Amaya, F Siddiqui, H Desai, JL Francis, Thromb Haemost 2002 87 930 936 12083498
75. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. AM Gil-Bernabe, S Ferjancic, M Tlalka, L Zhao, PD Allen, JH Im, K Watson, SA Hill, A Amirkhosravi, JL Francis, JW Pollard, W Ruf, RJ Muschel, Blood 2012 119 3164 3175 10.1182/blood-2011-08-376426 22327225
76. Biology and clinical implications of CD133(+) liver cancer stem cells. S Ma, Exp Cell Res 2013 319 126 132 10.1016/j.yexcr.2012.09.007 22999864
77. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. S Liu, C Ginestier, SJ Ou, SG Clouthier, SH Patel, F Monville, H Korkaya, A Heath, J Dutcher, CG Kleer, Y Jung, G Dontu, R Taichman, MS Wicha, Cancer Res 2011 71 614 624 10.1158/0008-5472.CAN-10-0538 21224357
78. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-kappaB-mediated MMP-9 upregulation. H Long, R Xie, T Xiang, Z Zhao, S Lin, Z Liang, Z Chen, B Zhu, Stem Cells 2012 30 2309 2319 10.1002/stem.1194 22887854
79. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. CC Milsom, JL Yu, N Mackman, J Micallef, GM Anderson, A Guha, JW Rak, Cancer Res 2008 68 10068 10076 10.1158/0008-5472.CAN-08-2067 19074872
80. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. M Sade-Feldman, J Kanterman, E Ish-Shalom, M Elnekave, E Horwitz, M Baniyash, Immunity 2013 38 541 554 10.1016/j.immuni.2013.02.007 23477736
81. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. MJ Krisinger, V Goebeler, Z Lu, SC Meixner, T Myles, EL Pryzdial, EM Conway, Blood 2012 120 1717 1725 10.1182/blood-2012-02-412080 22802338
82. Modulation of the antitumor immune response by complement. MM Markiewski, RA DeAngelis, F Benencia, SK Ricklin-Lichtsteiner, A Koutoulaki, C Gerard, G Coukos, JD Lambris, Nat Immunol 2008 9 1225 1235 10.1038/ni.1655 18820683
83. VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. S Ferjancic, AM Gil-Bernabe, SA Hill, PD Allen, P Richardson, T Sparey, E Savory, J McGuffog, RJ Muschel, Blood 2013 121 3289 3297 10.1182/blood-2012-08-449819 23407548
84. Epidemiology, risk and outcomes of venous thromboembolism in cancer. A Falanga, L Russo, Hamostaseologie 2012 32 115 125 10.5482/ha-1170 21971578
85. The effect of low-molecular-weight heparin on cancer survival: a systematic review and meta-analysis of randomized trials. A Lazo-Langner, GD Goss, JN Spaans, MA Rodger, J Thromb Haemost 2007 5 729 737 10.1111/j.1538-7836.2007.02427.x 17408406
86. The effect of low molecular weight heparin on survival in patients with advanced malignancy. CP Klerk, SM Smorenburg, HM Otten, AW Lensing, MH Prins, F Piovella, P Prandoni, MM Bos, DJ Richel, G van Tienhoven, HR Buller, J Clin Oncol 2005 23 2130 2135 10.1200/JCO.2005.03.134 15699479
87. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. RD Hull, G Townshend, Thromb Haemost 2013 110 14 22 10.1160/TH12-12-0931 23615656
88. Cellular mechanisms underlying the formation of circulating microparticles. O Morel, L Jesel, JM Freyssinet, F Toti, Arterioscler Thromb Vasc Biol 2011 31 15 26 10.1161/ATVBAHA.109.200956 21160064
89. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. G Hron, M Kollars, H Weber, V Sagaster, P Quehenberger, S Eichinger, PA Kyrle, A Weltermann, Thromb Haemost 2007 97 119 123 17200778
90. Microvesicle-associated tissue factor and Trousseau's syndrome. I Del Conde, LD Bharwani, DJ Dietzen, U Pendurthi, P Thiagarajan, JA Lopez, J Thromb Haemost 2007 5 70 74 10.1111/j.1538-7836.2006.02301.x 17239164
91. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? ME Tesselaar, FP Romijn, IK Van Der Linden, FA Prins, RM Bertina, S Osanto, J Thromb Haemost 2007 5 520 527 10.1111/j.1538-7836.2007.02369.x 17166244
92. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. ME Tesselaar, FP Romijn, IK van der Linden, RM Bertina, S Osanto, J Thromb Haemost 2009 7 1421 1423 10.1111/j.1538-7836.2009.03504.x 19500241
93. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. JI Zwicker, HA Liebman, D Neuberg, R Lacroix, KA Bauer, BC Furie, B Furie, Clin Cancer Res 2009 15 6830 6840 10.1158/1078-0432.CCR-09-0371 19861441